Molecular marker for predicting treatment response in advanced renal cell carcinoma: Does the promise fulfill clinical need?

Michael Garcia-Roig, Nicolas Ortiz, Vinata B Lokeshwar

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Renal cell carcinoma (RCC) is largely diagnosed incidentally on imaging taken for unrelated reasons. The management of localized lesions is primarily extirpative with excellent results. Treatment of advanced RCC has evolved over recent years with the use of targeted therapies such as tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, and antibody-mediated therapies. The treatment response to these targeted therapies is highly variable, with no clear clinical method of identifying patients who will benefit from or not tolerate therapy. The field of molecular markers has evolved significantly in the last decade, with a multitude ofmarkers identified that predict treatment response and drug toxicity. The following review critically evaluates those molecular markers that have been assessed for their utility in predicting treatment response in patients with advanced/metastatic renal cell carcinoma (mRCC). Identifying the ideal treatment for these patients will improve responses to therapy, minimize morbidity, and save significant healthcare dollars.

Original languageEnglish (US)
Article number375
JournalCurrent Urology Reports
Volume15
Issue number1
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Therapeutics
Sirolimus
Drug-Related Side Effects and Adverse Reactions
Protein-Tyrosine Kinases
Morbidity
Delivery of Health Care
Antibodies

Keywords

  • Metastatic renal cell carcinoma
  • Prognostic markers
  • Sorafenib
  • Sunitinib
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Urology

Cite this

Molecular marker for predicting treatment response in advanced renal cell carcinoma : Does the promise fulfill clinical need? / Garcia-Roig, Michael; Ortiz, Nicolas; Lokeshwar, Vinata B.

In: Current Urology Reports, Vol. 15, No. 1, 375, 01.01.2014.

Research output: Contribution to journalArticle

@article{be6b9ec6859643e780cc42f69a036bcb,
title = "Molecular marker for predicting treatment response in advanced renal cell carcinoma: Does the promise fulfill clinical need?",
abstract = "Renal cell carcinoma (RCC) is largely diagnosed incidentally on imaging taken for unrelated reasons. The management of localized lesions is primarily extirpative with excellent results. Treatment of advanced RCC has evolved over recent years with the use of targeted therapies such as tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, and antibody-mediated therapies. The treatment response to these targeted therapies is highly variable, with no clear clinical method of identifying patients who will benefit from or not tolerate therapy. The field of molecular markers has evolved significantly in the last decade, with a multitude ofmarkers identified that predict treatment response and drug toxicity. The following review critically evaluates those molecular markers that have been assessed for their utility in predicting treatment response in patients with advanced/metastatic renal cell carcinoma (mRCC). Identifying the ideal treatment for these patients will improve responses to therapy, minimize morbidity, and save significant healthcare dollars.",
keywords = "Metastatic renal cell carcinoma, Prognostic markers, Sorafenib, Sunitinib, Tyrosine kinase inhibitors",
author = "Michael Garcia-Roig and Nicolas Ortiz and Lokeshwar, {Vinata B}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s11934-013-0375-0",
language = "English (US)",
volume = "15",
journal = "Current Urology Reports",
issn = "1527-2737",
publisher = "Current Science, Inc.",
number = "1",

}

TY - JOUR

T1 - Molecular marker for predicting treatment response in advanced renal cell carcinoma

T2 - Does the promise fulfill clinical need?

AU - Garcia-Roig, Michael

AU - Ortiz, Nicolas

AU - Lokeshwar, Vinata B

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Renal cell carcinoma (RCC) is largely diagnosed incidentally on imaging taken for unrelated reasons. The management of localized lesions is primarily extirpative with excellent results. Treatment of advanced RCC has evolved over recent years with the use of targeted therapies such as tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, and antibody-mediated therapies. The treatment response to these targeted therapies is highly variable, with no clear clinical method of identifying patients who will benefit from or not tolerate therapy. The field of molecular markers has evolved significantly in the last decade, with a multitude ofmarkers identified that predict treatment response and drug toxicity. The following review critically evaluates those molecular markers that have been assessed for their utility in predicting treatment response in patients with advanced/metastatic renal cell carcinoma (mRCC). Identifying the ideal treatment for these patients will improve responses to therapy, minimize morbidity, and save significant healthcare dollars.

AB - Renal cell carcinoma (RCC) is largely diagnosed incidentally on imaging taken for unrelated reasons. The management of localized lesions is primarily extirpative with excellent results. Treatment of advanced RCC has evolved over recent years with the use of targeted therapies such as tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, and antibody-mediated therapies. The treatment response to these targeted therapies is highly variable, with no clear clinical method of identifying patients who will benefit from or not tolerate therapy. The field of molecular markers has evolved significantly in the last decade, with a multitude ofmarkers identified that predict treatment response and drug toxicity. The following review critically evaluates those molecular markers that have been assessed for their utility in predicting treatment response in patients with advanced/metastatic renal cell carcinoma (mRCC). Identifying the ideal treatment for these patients will improve responses to therapy, minimize morbidity, and save significant healthcare dollars.

KW - Metastatic renal cell carcinoma

KW - Prognostic markers

KW - Sorafenib

KW - Sunitinib

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84893031630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893031630&partnerID=8YFLogxK

U2 - 10.1007/s11934-013-0375-0

DO - 10.1007/s11934-013-0375-0

M3 - Article

C2 - 24337833

AN - SCOPUS:84893031630

VL - 15

JO - Current Urology Reports

JF - Current Urology Reports

SN - 1527-2737

IS - 1

M1 - 375

ER -